Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AGEN -- Ignore unavailable to you. Want to Upgrade?

To: Constant Reader who wrote (8)	6/21/2001 9:40:23 AM
From: Harry J.	Respond to of 15

Antigenics Receives Key Patents Expanding Its Immunology Platforms [pulled from the SI:News page for AGEN] NEW YORK, Jun 21, 2001 /PRNewswire via COMTEX/ -- Antigenics Inc. (Nasdaq: AGEN chart, msgs) announced today that it was issued a U.S. patent (No. 6,231,859) that will expand the scope of potential applications for the company's Stimulon(R) family of adjuvants. The patent covers novel combinations of the QS-21 immune adjuvant with additional saponin adjuvants resulting in synergistic adjuvant activity. In dose optimization studies, it has been found that a combination of low dose QS-21 and QS-7, an adjuvant active fraction of Quillaja saponaria, has the same beneficial immune effect as conventional doses of QS-21, but results in a milder vaccine formulation than does QS-21 alone. Such combinations may be useful for vaccine formulations that have stringent requirement for reactogenicity, such as pediatric vaccines. [snip] Regards, Harry J.

To: Constant Reader who wrote (8)	10/15/2001 11:00:18 PM
From: Harry J.	Read Replies (1) \| Respond to of 15

Thread (& CR) - "Antigenics' Oncophage(R) Becomes First Personalized Cancer Product To Receive FDA Fast Track Designation" "NEW YORK, Oct 15, 2001 /PRNewswire via COMTEX/ -- Antigenics Inc. (Nasdaq: AGEN chart, msgs) announced today that the U.S. Food and Drug Administration (FDA) has designated Oncophage(R), the company's personalized cancer vaccine, a Fast Track Product for the treatment of renal cell carcinoma. [snip]" Go to SI:News for AGEN to see the rest of the press release. Regards, Harry